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Cochrane Dementia Group turns 21 – older and (slightly) wiser 
The Cochrane Dementia Group or, to use its full title, the Cochrane Dementia and Cognitive 
Improvement Group (CDCIG), was founded in 1995.  To mark this 21st anniversary, in September 
2016 more than 60 members, contributors and colleagues of CDCIG from around the world 
celebrated with a conference and party in the group's birthplace, the University of Oxford.  As part 
of the meeting, we participated in some group reminiscence, led by Leon Flicker, one of the group's 
early editors.  As we reflected on the development, achievements and future aims of the group, it 
became clear that the lessons learned over the years remain relevant to the group and to the 
broader dementia research community. 
For those unfamiliar with it, Cochrane (www.cochrane.org) is a global network that strives to 
produce credible and accessible information to inform healthcare decision-making by patients and 
clinicians.  The epidemiologist Archie Cochrane recognised the importance of collating all available 
evidence.1  The resulting Cochrane Collaboration remains best known for producing systematic 
reviews and meta-analyses, although its interest extends to many aspects of evidence synthesis, 
most notably development of methodology.  With the number of meta-analyses in the medical 
literature increasing exponentially, Cochrane reviews are internationally recognised as a gold 
standard of evidence due to their adherence to strict methodological standards.   
Under the umbrella of Cochrane are a series of themed groups.  When it started in 1995, Cochrane 
Dementia had a small team of editors and published a handful of reviews. CDCIG now has a portfolio 
of over 180 active systematic reviews covering interventions and tests for dementia and other 
cognitive disorders; an editorial board of 22 from diverse disciplines including geriatric medicine, 
psychiatry, nursing, pharmacology, psychology and public health; all supported a managing editor, 
information specialist and search coordinator.  This growth is testament to a transformation in the 
amount and status of dementia research, something which seemed implausible back in 1995 when 
there were few trials of dementia interventions and little political or public interest. 
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The timing of the development of the Cochrane dementia group was opportune as the early 
dementia pharmacological interventions were evaluated with substandard methodology. The first 
drug to be eventually licensed for the treatment of Alzheimer’s Disease, Tacrine, had initial 
unbelievably positive results reported.2 However, defects in the trial methodology and reporting 
were soon noted and a FDA investigation found many irregularities.3  Subsequently independent 
positive studies appeared that found more modest effects, as well as hepatic toxicity, effectively 
summarized in an individual patient data review.4  The need for more rigorous methodology and  
more accurate reporting was clear and Cochrane Dementia has always had a role in supporting and 
campaigning for greater transparency and methodological rigour.  Cholinesterase inhibitors now 
have an established role in the treatment of patients with Alzheimer ’s disease although the most 
recent Cochrane review concludes that effects are modest and often associated with cholinergic side 
effects.5  Unfortunately, the field continues to be plagued by trial results that are spectacularly 
positive6 yet disappointingly are unable to be replicated.7 
The story of Tacrine remains pertinent to contemporary dementia research.  The massive increase in 
public interest and in the commercial potential of dementia, has only served to multiply the appetite 
for stories of 'breakthroughs' and 'cures' for dementia.  Core to the purpose of CDCIG is to subject 
the evidence about interventions to critical scrutiny.  Unfortunately, there are few reviews in the 
portfolio which identify benefits of treatment with certainty.  An accusation often levelled at 
Cochrane is that most reviews end with the same conclusion: “…….there is no convincing evidence to 
support use of X”.  We make no apology for subjecting the evidence about interventions to rigorous 
testing.  We are neither nihilistic nor pessimistic regarding dementia treatment, but we believe 
progress will only come through a clear-eyed approach to current knowledge. 
Currently, the greatest scientific speculation and controversy in the field of dementia is not around 
treatment, but diagnosis.  Making a robust diagnosis is an important facet of dementia 
management.  CDCIG was among the first Cochrane groups to publish reviews of diagnostic test 
3 
 
accuracy, offering a suite of reviews describing the accuracy and utility of various approaches to 
dementia diagnosis.  The reviews covered neuroimaging and tissue based assays as well as short 
cognitive screening tests.8  This work was timely as it coincided with new diagnostic proposals which 
suggested the use of imaging and cerebrospinal fluid biomarkers in the diagnosis of dementia and 
pre-dementia states.9  Again, CDCIG sounded a note of caution that was not in keeping with the 
general excitement and enthusiasm regarding biomarkers.  The body of evidence to support the use 
of biomarkers was, and still is, relatively modest in size and the available studies had a number of 
methodological limitations.10  Our formal evaluation quantitative of sensitivity and specificity found 
that certain dementia biomarkers had accuracy metrics that were less than would usually be 
required to recommend use of a test in clinical practice.11 
CDCIG has always strived to be more than just a passive collector of evidence and the group has had 
a role in raising standards in conduct and reporting of science.  As an example, we supported our 
work on dementia test accuracy to create specific reporting guidance for the dementia field 
(STARDdem).12  This was complemented by template protocols for those wishing to conduct 
dementia test accuracy reviews13 and methodological papers looking at the science of dementia test 
accuracy analyses.14  We hope that these materials will bear fruit over time, although we note that 
recent high profile reviews of biomarkers have not followed best practice recommendations.15 
Although CDCIG's early intervention reviews were largely of drug trials, these no longer make up the 
bulk of our activity, again reflecting the broadening of interest in dementia across researchers of 
many different disciplines.  Highly accessed content from last year includes music therapy16, 
reminiscence17 and cognitive stimulation.18  Several of our reviews with 'positive' findings are of 
psychosocial interventions, e.g. multicomponent interventions to prevent delirium.19  Psychosocial 
interventions can also come with vested interests and have lagged behind drug trials in the quality of 
trial design and reporting (although the landscape is changing). Hence, Cochrane's systematic review 
methods, emphasising the importance of assessing risk of bias, are just as pertinent. Increasingly 
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dementia studies are looking at the effects of complex (systems based) interventions and adopting 
appropriate methods for synthesis of these data is another current interest in the group.   
Using reviews of existing research is useful to summarise what is already known but can also be a 
powerful tool for guiding future primary research.  Historically, variations on the review conclusion 
of “more research is needed” are at least as common as “there is no convincing evidence”, and 
equally frustrating for readers.  One of CDCIG's current aims is to improve reviews by drawing more 
specific implications for future research.  This is a theme of a recent programme of work looking at 
modifiable risk factors for dementia.  There is much interest in whether lifestyle modifications could 
alter the course of cognitive decline and CDCIG have collated the evidence with an emphasis on 
some of the more recently proposed modifiable risk factors.  Titles include computerised cognitive 
training, dietary and exercise interventions and whether discontinuation of medications such as 
antihypertensives has an effect on cognitive decline.20  Not all the reviews in the suite are complete 
but a common theme is emerging.  For certain interventions, pooled data suggest a signal of 
potential effect, but the summary estimates do not reach statistical significance.  Positive trends in 
the data are encouraging but are not enough to change practice.  Hoping not to confine ourselves to 
the anodyne “more research is needed”, CDCIG is now working with methodologists and statisticians 
to explicitly define which research questions would benefit from further original data, what should 
these studies look like and how much data are needed to give a definitive answer.  
Along with publication of systematic reviews, all Cochrane review groups are tasked with the 
creation and maintenance of a register of clinical trials in their area of interest. In 2008, with the 
support of the Alzheimer's Association, CDCIG created ALOIS, a register of dementia trials, 
containing bibliographic and other information on controlled trials in dementia and related areas, 
that is updated monthly (www.medicine.ox.ac.uk/alois).  ALOIS is the focus of pioneering public 
engagement work, recruiting volunteers, many of whom were carers and former carers, to help 
populate ALOIS by extracting characteristics of trials. Cochrane Dementia has established a 
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reputation for consumer/patient involvement in evidence production.  The information specialist 
within the group now co-leads Cochrane Crowd (http://crowd.cochrane.org) a crowdsourcing 
platform, with a community of over 3,500 volunteers who have helped identify almost 30,000 
reports of randomised trials across many healthcare areas.  Cochrane Crowd builds on all that we 
have learnt over the last 8 years in terms of providing better opportunities for people to be able to 
contribute meaningfully and usefully to the work of Cochrane. 
As we look forward, we recognise that systematic review is evolving in line with methodological and 
technological advances.  Reviews of dementia treatments compared to a control will remain core 
work for the group and we are excited that potential new treatments are emerging from early phase 
work.  The process of the systematic review is likely to change with techniques like semi-automation 
allowing improved efficiency.  However, the methodological precision and complete impartiality that 
has defined Cochrane reviews will not change.  To meet the needs of an ever changing health-care 
system, it seems likely that CDCIG will also evolve.  A direction of travel is to complement traditional 
review work, with more sophisticated reviews that incorporate economic evaluation; qualitative 
data and multicomponent network analyses.  Communicating this science is key and we will 
continue to share important reviews through various social media.  We would welcome users to 
follow us on twitter @CochraneDCIG.  CDCIG’s greatest strength lies in the researchers, clinicians, 
information scientists and lay public who contribute to our work.  We are happy to welcome new 
members, particularly those with a passion for evidence based healthcare who are not afraid to 
challenge the status quo in dementia research.  Happy Birthday Cochrane Dementia, here’s to the 
next 21 years.  
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